Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Carisbamate as Adjunctive Therapy in Subjects With Partial Onset Seizures, Followed by an Open-Label Extension Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Aug 2021
Price :
$35
*
At a glance
- Drugs Carisbamate (Primary)
- Indications Partial epilepsies
- Focus Registrational; Therapeutic Use
- Sponsors SK Life Science
- 31 Jul 2021 The Extension study has been completed in Spain (Global end date: 31 Aug 2010), as per European Clinical Trials Database record (EudraCT2008-005098-37).
- 31 Jul 2021 The Extension study has been completed in Spain (Global end date: 31 Aug 2010), as per European Clinical Trials Database record (EudraCT2008-005098-37).
- 31 Jul 2021 The Extension study has been completed in Spain (Global end date: 31 Aug 2010), as per European Clinical Trials Database record (EudraCT2008-005098-37).